Proposed DSM/Kensey Nash deal draws legal scrutiny; Smith & Nephew closes Kalypto buy;

@FierceMedDev: Corporate Whistle Blower Center unveils initiative vs. "very corrupt US medical device industry." Release | Follow @FierceMedDev

> The law firm Levi & Korsinsky is investigating Kensey Nash's ($KNSY) board of directors for possible breaches of fiduciary duty and other potential violations of state law regarding its proposed $360 million sale to Royal DSM ($DSM). Release

> Smith & Nephew ($SNN) has closed its acquisition of the privately held Kalypto Medical, a maker of the NPD 1000 portable, ambulatory negative pressure wound therapy system. Release

> Major medical device clusters in areas such as California, Pennsylvania, Massachusetts and North Carolina face increased competition from emerging clusters in Michigan, Indiana, Georgia, Ohio, Texas and Colorado, according to a new report. Story

> New Medicare device and equipment purchasing rules set to fully roll out in January include competitive bidding, traceable ID numbers for supplies and regulations designed to reduce extra cost and fraud in dispensing diabetes equipment. News

> New CD Diagnostics CEO Rick Birkmeyer plans to move the joint fluid analysis company from an incubator in Pennsylvania to Delaware, and employ 170 people there by 2015. Item

> Toronto researchers are exploring whether they can implant a user interface that lets patients interact directly with their implanted medical devices. Report

> CardioKinetix has hired Maria Sainz, a veteran executive from Stryker Neurovascular ($SYK), as its new president and CEO. Release

> Modern Mobility Aids has hashed out a deal with Lumigene Technologies to develop and commercialize molecular diagnostic products. Release

Pharma News

@FiercePharma: Pharma's biggest companies saw aggregate profits rise 12.8% on a slight uptick in sales last year, Pharmabiz finds. Report | Follow @FiercePharma

> Truvada up for FDA debate as HIV preventive. More

> Congress drags Big Pharma into Obamacare negotiation probe. Article

Biotech News

@FierceBiotech: Roche abandons potential blockbuster cholesterol drug, bringing negative attention to similar drugs. News | Follow @FierceBiotech

@RyanMFierce: Report says that a pharma startup operating in the offices of Lilly's VC unit raised $4.6M. Story | Follow @RyanMFierce

@MarkHFierce: Folks, we're still taking nominations for the 15 fiercest private device developers. Make them here: Survey | Follow @MarkHFierce

> Roche abandons potential blockbuster cholesterol drug. News

> Novartis passes Phase III test for rare-disorder drug. Item

> FDA harps on risks of Pfizer's tofacitinib as panel looms. Report

Biotech IT News

> Medidata snags biz from rival Oracle in record Q1. News

> Investors pour $50.8M into genomics standout Oxford Nanopore. News

> Startup tries Apple-like strategy in genomics field. Item

> Software provider to Merck taps IBM cloud to fight fake drugs. Article

> A case for 'open source' clinical trial data (locked behind a pay wall). More

> Genomics tops chart of social media buzz in biotech IT. Report

And Finally... CBS's "Sunday Morning" program reports about Dr. Kevin Pauza, a founder of the Texas Spine and Joint Hospital who has developed a procedure through which thrombin and fibrinogen are combined into a gel and injected into the spine to help repair and regrow discs. Story

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.